November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

FDA Approves First New Class of Schizophrenia Medication in Decades

❤️ Conditions & Care 1 min read 👁 5

Federal regulators have approved a novel antipsychotic medication called Cobenfy, marking a significant shift from decades-old dopamine-targeting treatments.

FDA Approves First New Class of Schizophrenia Medication in Decades❤️Conditions & Care

Photo: everydayhealth.com

Key points

  • FDA approved Cobenfy capsules in September 2024 for adults with schizophrenia.
  • It is the first muscarinic agonist, targeting cholinergic receptors instead of dopamine.
  • Common side effects include nausea, indigestion, and elevated blood pressure, but it does not cause weight gain.

In September 2024, the U.S. Food and Drug Administration approved xanomeline and trospium chloride, marketed as Cobenfy capsules, for treating adult schizophrenia. According to reports from Everyday Health, this approval introduces the first new class of antipsychotic medications in decades. Unlike traditional treatments that focus primarily on brain dopamine pathways, this new muscarinic agonist targets cholinergic receptors to manage symptoms without typical weight gain side effects.

Clinical data highlights that while the medication avoids weight gain, it may bring other side effects such as nausea, indigestion, constipation, dizziness, and elevated blood pressure. Beyond pharmaceuticals, health guidelines emphasize comprehensive approaches like Coordinated Specialty Care—supported by the National Institute of Mental Health through the RAISE initiative—and electroconvulsive therapy for treatment-resistant symptoms.

What to know: Patients and caregivers are encouraged to learn about the condition and discuss personalized options with a qualified healthcare provider.

Source everydayhealth.com — everydayhealth.com/mental-health-conditions/schizophrenia-care/ ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.